NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

Core Insights - NLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, focusing on small molecules that target arousal stability, cognition, and neuroprotection [1][4] - AEX-635, a lead compound, modulates MRP1, enhancing neuroprotective effects and improving CNS drug bioavailability, particularly in conditions like Parkinson's disease [1][3] Platform Expansion - The AEX-6xx program broadens the translational scope of the DOXA platform, integrating dual orexin receptor agonism with cathepsin H inhibition to address sleep-wake regulation and neuronal resilience [3][4] - The DOXA series aligns with the mission of NewCelX, the combined entity of NLS and Kadimastem, to innovate in neuroscience and cell therapy for neurological and metabolic disorders [4] Financial Position - NLS raised approximately $7 million in equity financing and secured a $25 million equity line of credit, strengthening its cash position for upcoming operations [5][6] - The financing is expected to support clinical programs and ensure the company is well-capitalized for at least the next 12 months [5] Preclinical Highlights - The DOXA platform shows up to 80% reduction in cataplexy and over 70% increase in wakefulness in narcolepsy models, demonstrating sustained efficacy without orexin receptor desensitization [9] - The platform exhibits robust neuroprotective activity under stress conditions, with potential applications in Type 1 Narcolepsy, ADHD, and neurodegenerative diseases [9][10] Intellectual Property - The AEX-6xx series is protected under international patent applications, advancing through national phases in key markets including the US, EU, and Japan [11] Strategic Next Steps - NLS and Aexon Labs are preparing for preclinical partnering discussions and plan to launch a unified brand identity under NewCelX, emphasizing their cross-continental model [12]